GlassScriptPhysician profile
Ayesha Cheema
NPI 1083617617
$4,085.42
in general payments reported to CMS, 2019-2025
32 companies · $469 in 2025
The $469 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,176 · 2020: $966 · 2021: $821 · 2022: $133 · 2023: $156 · 2024: $364 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.75 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $822.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $641.47 | 2019-2025 | Jardiance, Lyumjev, Baqsimi |
| Astrazeneca Pharmaceuticals LP | $287.93 | 2019-2022 | |
| Abbvie INC. | $285.79 | 2019-2022 | |
| Amgen INC. | $217.40 | 2019-2025 | Tepezza, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $181.31 | 2019-2024 | |
| Amneal Pharmaceuticals LLC | $174.59 | 2019-2024 | Unithroid |
| Merck Sharp & Dohme LLC | $159.50 | 2019-2021 | |
| Dexcom, INC. | $144.43 | 2019-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $129.28 | 2019 | |
| Ibsa Pharma INC. | $113.44 | 2019-2024 | Tirosint, Licart, Flector |
| Insulet Corporation | $106.20 | 2019-2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $84.22 | 2025 | Strensiq |
| Corcept Therapeutics | $82.36 | 2019-2021 | |
| Antares Pharma, INC. | $81.91 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.52 | 2019-2021 | |
| Mannkind Corporation | $59.40 | 2023 | Afrezza |
| Tandem Diabetes Care, INC. | $54.27 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $52.64 | 2019-2021 | |
| Radius Health, INC. | $50.56 | 2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $36.35 | 2024-2025 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $36.22 | 2020-2023 | Tepezza |
| Medtronic, INC. | $32.65 | 2021 | |
| Ascendis Pharma Endocrinology INC | $28.13 | 2025 | Yorvipath |
| Ultragenyx Pharmaceutical INC. | $25.97 | 2024 | Crysvita |
| Medtronic Minimed, INC. | $25.21 | 2020 | |
| Amarin Pharma, INC. | $21.67 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.76 | 2025 | Hyqvia |
| Hologic Sales and Service, LLC | $15.84 | 2025 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $15.74 | 2022 | |
| Clarus Therapeutics INC. | $14.85 | 2021 | |
| Shire North American Group INC | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayesha Cheema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.